A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma

2025-522307-14-00 Protocol 0439-24 Human pharmacology (Phase I) - Bioequivalence study Ongoing, recruiting

Start 19 Jan 2026 · Status Ongoing, recruiting · 2 EU/EEA countries · 9 sites · Protocol 0439-24

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ongoing, recruiting
Participants planned 340
Countries 2
Sites 9

Melanoma

Key facts

Sponsor
Intas Pharmaceuticals Limited
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
19 Jan 2026 → ongoing
Decision date (initial)
2025-12-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Melanoma

VersionLevelCodeTermSystem organ class
21.1 LLT 10053571 Melanoma 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Intas Pharmaceuticals Limited

Sponsor organisation
Intas Pharmaceuticals Limited
Address
Plot No 423/P/A Sarkhej-Bavla Highway, Village Moraiya, Taluka-Sanand Village Moraiya Taluka-Sanand
City
Ahmedabad
Postcode
382213
Country
India

Scientific contact point

Organisation
Intas Pharmaceuticals Limited
Contact name
Dr. Anoop CH

Public contact point

Organisation
Intas Pharmaceuticals Limited
Contact name
Dr. Anoop CH

Locations

2 EU/EEA countries · 9 investigational sites

By country

CountryMS statusPlanned subjectsSites
Romania Ongoing, recruiting 19 3
Spain Ongoing, recruiting 15 6
Rest of world
Turkey, Moldova, Republic of, Brazil, Chile, Mexico, Bosnia and Herzegovina, Argentina, Korea, Republic of, South Africa
306

Investigational sites

Romania

3 sites · Ongoing, recruiting
Centrul De Oncologie SF Nectarie S.R.L.
Oncology, Strada Caracal Nr 109, 200542, Craiova
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
Oncology, Strada Republicii 34-36, 400015, Cluj-Napoca
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti
Oncology, Soseaua Fundeni 252, 022328, Bucharest

Spain

6 sites · Ongoing, recruiting
Hospital Universitario 12 De Octubre
Oncology, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitario Regional De Malaga
Oncology, Avenida De Carlos De Haya S/N, 29010, Malaga
Hospital Quironsalud Malaga
Medical Oncology, Avenida Imperio Argentina 1, 29004, Malaga
Hospital Universitario De Badajoz
Medical Oncology, Avenida Elvas S/n, 06006, Badajoz
Hospital Clinic De Barcelona
Oncology, Calle Villarroel 170, 08036, Barcelona
Hospital San Pedro De Alcantara
Medical Oncology, Avenida De Pablo Naranjo Porras S/n, 10002, Caceres

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Romania 2026-01-19 2026-01-20
Spain 2026-03-04 2026-04-15

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-08-11 Spain Acceptable
2025-12-01
2025-12-08
2 SUBSTANTIAL MODIFICATION SM-1 2026-01-14 Spain Acceptable 2026-02-13